Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG505 SOSIP.664 gp140 Vaccine in Healthy Adults
NCT03699241Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Dec 2018
- Primary completion
- Mar 2023
- Modality
- Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of BG505 SOSIP.664 gp140 in human immunodeficiency virus infection (HIV) (5 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 2 more. Started Dec 2018; status: completed.
02
Drugs
BG505 SOSIP.664 gp140
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03699241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699241.